Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP plus D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP) Meeting Abstract

  

Authors:	Autio, K. A.; Antonarakis, E. S.; Mayer, T. M.; Vaishampayan, U. N.; Shevrin, D. H.; Harrison, M. R.; Tagawa, S. T.; Milowsky, M. I.; Graff, J. N.; Beer, T. M.; Balar, A. V.; Stein, M.; Heath, E. I.; Armstrong, A. J.; Paller, C. J.; Nordquist, L. T.; Dayan, E. S.; Tse, K.; Heller, G.; Scher, H. I.
Abstract Title:	Phase 2, randomized, 3-arm study of abiraterone acetate and prednisone (AAP), AAP plus degarelix (AAP plus D), and degarelix (D) alone for patients (pts) with biochemically-recurrent prostate cancer (PC) following radical prostatectomy (RP)
Meeting Title:	54th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	36
Issue:	15 Suppl.
Meeting Dates:	2018 Jun 1-5
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2018-05-20
Start Page:	272s
Language:	English
ACCESSION:	WOS:000442916002127
DOI:	10.1200/JCO.2018.36.15_suppl.5016
PROVIDER:	wos
Notes:	Meeting Abstract: 5016 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/169405